Lu Chen
7 Papers
1 Citations
Lu Chen is an academic researcher. The author has contributed to research in topics: Medicine & Pharmacokinetics. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
An Integrated Population Pharmacokinetic Analysis for Posaconazole Oral Suspension, Delayed-Release Tablet, and Intravenous Infusion in Healthy Volunteers
TL;DR: The pharmacokinetic superiority of the delayed-release tablet was demonstrated under both fed and fasted conditions, compared with the oral suspension, and the impact of food on the bioavailability of the delay-released tablet was larger than anticipated, suggesting that administering the delays with food enhances absorption.
8
Use of Modeling and Simulation to Predict the Influence of Triazole Antifungal Agents on the Pharmacokinetics of Crizotinib
Lu Chen,Lixian Li,Wanyi Chen +2 more
TL;DR: The validated physiologically based pharmacokinetic models were applied to predict the drug‐drug interactions between crizotinib and different triazoles (voriconazoles, fluconazole, or itraconazole) in patients with cancer and voriconazole exhibited the most significant influence on the pharmacokinetics exposure of crizotonib.
3
Use of modeling and simulation to predict the influence of triazole antifungal agents on the pharmacokinetics of zanubrutinib and acalabrutinib
TL;DR: The physiologically-based pharmacokinetic models sufficiently characterized the pharmacokinetics of BTK inhibitors and triazole antifungals, and were used to predict untested clinical scenarios.
3
Drug-Drug Interactions and Dose Management of BTK inhibitors When Initiating Nirmatrelvir/Ritonavir (Paxlovid) Based on Physiologically-Based Pharmacokinetic Models.
Chao Li,Lu Chen,Lixian Li,Wanyi Chen +3 more
TL;DR: The prospective simulations provided scientific evidence regarding rational dosing management strategies when initiating nirmatrelvir/ritonavir therapy and provided a reference for the design of clinical DDIs study that may save resources and time.
3
Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults.
Lu Chen,K. van Rhee,Roeland E Wasmann,Elke H. J. Krekels,Marinus J. Wiezer,Eric P.A. van Dongen,Paul E. Verweij,P. D. Van Der Linden,Roger J. M. Brüggemann,Catherijne A. J. Knibbe +9 more
TL;DR: In the population of obese but otherwise healthy individuals, obesity clearly alters the pharmacokinetics of fluconazole, which puts severely obese adults, particularly if male, at risk of suboptimal exposure, for which adjusted doses are proposed.